Pharmaceuticals, Biotechnology and Life Sciences
Santhera Pharmaceuticals said Thursday that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in…
Together with partnering companies SCHOTT Pharma and Körber Pharma, Schreiner MediPharm is going to show how sustainable packaging design can combine waste and cost reduction with user convenience and patient safety.
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan.…
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.
Novartis said in a press release Monday that the Scottish Medicines Consortium (SMC) has published advice recommending Fabhalta (iptacopan) for…
Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.
Moderna announced Monday business updates and progress across its pipeline of mRNA medicines, entering 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need, as it achieved $3-3.1B in product sales.
Clarivate has released the twelfth annual Drugs to Watch report, its guide to the therapies poised to redefine the future of healthcare, highlighting 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Klinge Biopharma GmbH, the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea (Aflibercept),has signed a licensing agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel. In parallel Formycon has signed an agreement with Teva under which Formycon will supply the finished product.
QUANTRO Therapeutics has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets.